Physician profile
Chad Schoenmann
NPI 1740578863
$10,682.30
in general payments reported to CMS, 2019-2025
27 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,119 · 2022: $1,674 · 2023: $1,909 · 2024: $3,628 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,397 · Consulting Fee: $1,063 · Education: $275 · Travel and Lodging: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,397.18 |
| Consulting Fee | $1,062.50 |
| Education | $275.20 |
| Travel and Lodging | $154.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,138.50 | 2021-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $1,788.79 | 2021-2025 | |
| Lilly USA, LLC | $1,131.95 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $939.20 | 2021-2025 | |
| Abbvie INC. | $776.84 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $757.40 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $591.54 | 2023-2025 | Sotyktu |
| Leo Pharma INC. | $439.76 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $374.75 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $350.74 | 2021-2025 | Ilumya |
| Ucb, INC. | $310.53 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $169.44 | 2024-2025 | Nemluvio |
| Dermavant Sciences, INC. | $149.01 | 2022-2024 | Vtama |
| Incyte Corporation | $139.80 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $118.42 | 2023-2024 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.45 | 2022-2024 | Targretin, Siliq, Duobrii |
| Genentech USA, INC. | $69.84 | 2021-2022 | |
| Organon LLC | $60.24 | 2025 | |
| Amgen INC. | $59.37 | 2023-2025 | Otezla, Otezla |
| Almirall LLC | $55.57 | 2021-2024 | Seysara |
| Mayne Pharma Commercial LLC | $43.67 | 2022-2025 | |
| Kerecis Limited | $39.95 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mallinckrodt Hospital Products INC. | $26.62 | 2025 | Acthar |
| Medtronic, INC. | $19.58 | 2025 | Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.03 | 2025 | Spevigo |
| Fresenius Kabi USA, LLC | $16.24 | 2023 | Idacio |
| Glaxosmithkline, LLC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Schoenmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.